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Abstract Aw o m a n ’s risk for metabolic syndrome (MS)
increases at menopause, with an associated increase in risk
for cardiovascular disease. We hypothesized that early
menopause-related changes in platelet activity and concen-
trations of microvesicles derived from activated blood and
vascular cells provide a mechanistic link to the early
atherothrombotic process. Thus, platelet functions and cellular
origin of blood-borne microvesicles in recently menopausal
women (n=118) enrolled in the Kronos Early Estrogen
Prevention Study were correlated with components of MS
and noninvasive measures of cardiovascular disease [carotid
artery intima medial thickness (CIMT), coronary artery
calcium (CAC) score, and endothelial reactive hyperemic
index (RHI)]. Specific to individual components of the MS
pentad, platelet number increased with increasing waist
circumference, and platelet secretion of ATP and expression
of P-selectin decreased with increasing blood glucose (p=
0.005) and blood pressure (p<0.05), respectively. Waist
circumference and systolic blood pressure were independent-
ly associated with monocyte- and endothelium-derived
microvesicles (p<0.05). Platelet-derived and total procoagu-
lant phosphatidylserine-positive microvesicles, and systolic
blood pressure correlated with CIMT (p<0.05), but not
with CAC or RHI. In summary, among recently menopausal
women, specific platelet functions and concentrations of
circulating activated cell membrane-derived procoagulant
microvesicles change with individual components of MS.
These cellular changes may explain in part how meno-
pause contributes to MS and, eventually, to cardiovascular
disease.
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Introduction
The risk for developing cardiovascular disease in women
increases after menopause, in part because of susceptibility
to developing metabolic syndrome [1–3]. Metabolic syn-
drome is characterized by the presence of three of five
clinical parameters including: waist circumference >35 in.
(>88 cm), high-density lipoprotein cholesterol (HDL-C)
<50 mg/dL, triglyceride level >150 mg/dL, fasting blood
glucose >100 mg/dL, and systemic blood pressure (systolic
blood pressure≥130 or diastolic blood pressure ≥85 mmHg)
[4, 5]. Using that characterization, two individuals may be
described with metabolic syndrome, but the underlying
pathways affecting specific vascular or metabolic functions
may differ. A components model of metabolic syndrome
identified an association of high triglycerides and hyper-
tension with myocardial infarction and stroke in a subset of
women (20–89 years of age) sampled in the Third National
Health and Nutrition Examination Study (NHANES III)
[6]. However, precise mechanisms by which components of
the metabolic syndrome may contribute, equally or syner-
gistically, to early processes of cardiovascular disease are
unknown.
Platelets, derived from megakaryocytes in the bone
marrow, are blood-borne elements implicated in the progres-
sion of cardiovascular disease [7–10]. Platelets turnover
within about a 10-day period, during which time changes
in the reactivity of individual platelets may progress through
stages of aggregation, secretion, adhesion, expression of
procoagulant surface (phosphatidylserine, P-selectin, and
fibrinogen receptors), and shedding of thrombogenic
membrane vesicles. This turnover is influenced by
hormonal and metabolic influences on the megakaryocytes
[11, 12]. No studies have evaluated the relationships of
platelet functions and metabolic syndrome with subclinical
measures of atherosclerosis in asymptomatic but at-risk
population.
Activated platelets, as well as other vascular cells,
release membrane-derived microvesicles [13, 14]. Popula-
tions of prothrombotic cell membrane-derived microve-
sicles increased with the presence of arterial calcification in
otherwise healthy menopausal women [15] and with
metabolic syndrome [16, 17]. Therefore, further analysis
of the cellular origin of circulating microvesicles may
provide insight into the activation of the vasculature with
metabolic syndrome in the earliest stages of cardiovascular
disease. This study was designed to evaluate platelet
characteristics and activated vascular and blood cell-derived
microvesicles with components of metabolic syndrome in
recently menopausal women in whom the overall immediate
cardiovascular disease risk is low but longitudinal risk will
increase due to their menopausal status [18–20]. It was
hypothesized that platelet reactivity and platelet-derived
microvesicles would correlate positively with components
of metabolic syndrome, carotid artery intima medial thick-
ness (CIMT), and coronary arterial calcification (CAC)
but negatively correlate with peripheral forearm reactive
hyperemia.
Methods
Subjects
Studysubjectswererecentlymenopausalwomen(42–59years
old, within 6 months to 3 years of their last menses) without
known or suspected cardiovascular disease and meeting the
inclusion criteria for the Kronos Early Estrogen Prevention
Study(KEEPS;NCT000154180)enrolledattheMayoClinic,
Rochester, MN [21]. KEEPS is a multicenter, randomized,
double-blinded, placebo-controlled trial designed to test the
hypothesis that hormone therapy started early in menopause
will reduce the onset, incidence, and progression of
subclinical atherosclerosis as defined by measurable changes
in CIMT and CAC. Each potential subject underwent a
medical examination, including body morphometrics (body
mass index, waist/hip ratio measurements), standard blood
chemistries, and an electrocardiogram. All women (n=118)
underwent high-resolution B-mode ultrasound for the as-
sessment of CIMT [22] and computed tomography for the
assessment of CAC (Siemens Sensation 64, Siemens
Medical Solutions, Forcheim, Germany) [15, 18]. A subset
of women (n=95) had assessment of forearm reactive
hyperemia by digital tonometry (reactive hyperemic index
or RHI) [23]. Women were excluded from KEEPS if they
had a history of clinically defined cardiovascular disease;
were current heavy smokers (more than ten cigarettes/day by
self-report); their CAC score was ≥50 Agatston units (AU);
body mass index was >35 kg/m
2; or if they had dyslipidemia
(low-density lipoprotein cholesterol >190 mg/dL), hyper-
triglyceridemia (triglycerides, >400 mg/dL), 17β-estradiol
>40 mg/dL, uncontrolled hypertension (systolic blood
pressure >150 mmHg and/or diastolic blood pressure
>95 mmHg), or fasting blood glucose >126 mg/dL [18,
21]. This study was approved by the Mayo Clinic Institu-
tional Review Board (IRB no. 2241-04 and no. 09-003464).
All participants gave written informed consent. For the
present study, we used blood samples from women (n=118)
meeting the KEEPS inclusion criteria at Mayo Clinic
Rochester; all samples were collected at baseline and prior
to randomization to study treatments.
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Total cholesterol, low-density lipoprotein cholesterol (LDL-
C) and HDL-C, triglycerides, blood glucose, follicle-
stimulating hormone, 17β estradiol, thyroid-stimulating
hormone, high-sensitivity C-reactive protein (hs-CRP) and
total protein, albumin, bilirubin, alkaline phosphatase,
aspartate, and alanine transaminases were measured by
Kronos Science Laboratories (Phoenix, AZ) and the Mayo
Clinic Department of Laboratory Medicine and Pathology
(Rochester, MN). Total white blood cells, differential
leukocytes, hemoglobin, and hematocrit were determined
by Mayo Clinic Hematopathology Laboratories. Platelet
count was determined by Coulter counter.
Blood Collection and Platelet Reactivity Assays
No participant was diabetic or taking lipid-lowering drugs
(inclusion criteria). Women were asked to refrain from
using aspirin for 10 days prior to the blood collection.
Fasting venous blood was collected into a syringe from an
antecubital venipuncture with a 19-gauge butterfly needle.
Blood was dispensed into plastic tubes containing anti-
coagulants needed for each assay as indicated below and
maintained at 33°C until the test was performed. To provide
consistency for platelet collection and handling, all samples
were processed within 30 min of collection by the same
individuals. With these collection techniques, platelet
activation as determined by basal expression of P-selectin
and fibrinogen receptors is <5% [15].
Platelet microaggregation was measured as the quotient
of platelet counts in blood samples collected in citrate and
EDTA anticoagulants [24, 25] and is reported as the
percentage of the difference. Platelet counts were corrected
for dilution by citrate anticoagulant; there was no signifi-
cant dilution in EDTA.
Platelet dense body ATP secretion from diluted platelet-
rich plasma was measured in real time by bioluminescence
using premixed firefly luciferase (0.5 mg/mL Hanks’ medium)
and luciferin (5 mM in Hanks’ medium) at 32°C and a final
platelet concentration of approx. 250–500 platelets/μL[ 26].
In brief, platelet-rich plasma prepared from citrate whole
blood and from blood anticoagulated with thrombin inhibitor
(hirudin, micromolar final) and a Factor Xa inhibitor
[10 μM, tick anticoagulant peptide (TAP) or soy bean
trypsin inhibitor (SBTI)] centrifugation at 200×g for 15 min
was diluted into 500–1000 volumes of Hanks’ medium
(Hanks’ balanced salt solution buffered to pH 7.4 with
20 mM HEPES and containing 3 mg/mL bovine albumin,
0.4 g/L glucose, and 1 μM TAP or SBTI). Thrombin receptor
agonist peptide (TRAP, 10 μM) was used as agonist for ATP
secretion assay. Dense body ATP secretion is expressed as
attomoles (amol)/platelet.
Platelet PGE1 sensitivity is a surrogate measure for
prostacyclin, which raises cAMP and thereby inhibits
platelet responses to agonists, including TRAP. This assay
is carried out in tandem with the ATP secretion assay. Prior
to assay, diluted platelets (250–500/μL) in Hanks’ medium
were incubated with PGE1 (∼500 nM) for 10 min at 32°C.
PGE1 sensitivity is expressed as percent suppression of
dense body ATP secretion.
Platelet membrane expression of P-selectin and the
fibrinogen-binding conformation of receptor integrin αIIbβ3
were measured by flow cytometry [24] with the following
modifications [15]. Platelets in whole blood (anticoagulated
with hirudin and Factor Xa inhibitor) were diluted 1:100 in
Hanks’ medium and then stimulated with agonist, ADP
(100 μM) or STRAP (10 μM), for 10 min. Platelets were
then stained with anti-GPIIIa (CD61) plus anti-P-selectin and
CD61plusanti-αIIBβ3 (PAC1) antibodies for 30 min at room
temperature. Platelets were fixed with 1% paraformaldehyde
in HEPES-buffered saline (HBS) prior to analysis by flow
cytometry (FACScalibur
TM, Becton Dickinson). Forward
scatter (for size characteristic) and log side scatter (for
refractive index) with CD61 antibody were used to identify
platelets. The platelet cloud was gated to exclude red and
white blood cells. Surface expressions of P-selectin and
fibrinogen receptors are expressed as percent positive.
Plasma-Activated Protein C
Mouse anti-human APC (HAPC 1555) was bound to
magnetic beads coated with goat anti-mouse IgG. Beads
were separated from liquid by use of an EasySep
TM magnet
(StemCell Technologies Seattle, WA). Beads from 2.5 mL
of the suspension provided by the manufacturer were
washed with 3×1 mL of 0.15 M NaCl, 5 mM CaCl2,
0.02 M Na–HEPES, pH 7.5 (HBS+Ca(II)). Beads were
then mixed with 0.5 mL of the anti-aPC (350 μg/mL in the
same buffer) for 5 h on a rotary mixer. Beads bound one
half of the protein as determined by the BCA protein assay.
Beads were suspended in 1.5 mL of 0.1 M NaCl, 0.02%
NaN3, and 0.05 M Tris–Cl, pH 7.4, and stored at 4°C until
used. On the week of planned use, the anti-aPC beads were
blocked with bovine serum albumin (BSA). In a 1.5-mL
polypropylene tube, 30 μL of beads, 1 mL 1% BSA in
HBS+Ca(II), 10 μL of 10% NP40, and 10 μL of 10% PEG
8000 were mixed on a rotary mixer for 1 h. The blocked
beads were then stored in the blocking solution at 4°C until
used. Venous blood (4 mL) was added to a tube containing
0.5 mL of 0.11 M sodium citrate and 0.1 mL of 1 M
benzamidinium Cl. Plasma was prepared within 30 min of
phlebotomy, and 1 mL of the plasma was added to the
blocked anti-aPC beads from which the blocking solution
had been removed and to which 15 μL of 100 μM hirudin
in HBS and 50 μL of a mixture of 1 M CaCl2 in HBS, 1 M
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(1:2:1:1) had been added. Plasma was mixed with the beads
on a rotary mixer for 90–180 min. Beads were washed and
assayed for bound plasma-activated protein C (aPC) with
fluorescent substrate SN-59 (D-Val-Pro-Arg-6-amino-1-
naphthalene sulfonamide). Assays were carried out in
duplicate. For a standard curve, authentic human aPC was
added to 1 mL of 1% BSA in HBS+Ca(II) plus 15 μLo f
100 μM hirudin and 50 μL of a mixture (1:2:1:1) of 1 M
CaCl2,1MN a –HEPES (pH 7.5), 10% NP40, and 10%
PEG 8000. The standard solutions were added to blocked
aPC beads, mixed, and assayed with the plasma samples.
Standards prepared by adding aPC to pooled normal human
citrated plasma from CRYOcheck
TM gave equivalent
results.
Microvesicles
The cellular origin and expression of the procoagulant
(phosphatidylserine) surface of the circulating population of
microvesicles (MV) were determined in platelet-free plasma
from hirudin and SBTI anticoagulated blood as described
previously [15]. Platelet-free plasma was prepared within
30 min of blood collection and stored at −70°C until
analysis.
Materials
The TRAP (H2N-Ser-4-fluoro-Phe-2-naphthyl-Ala-Leu-
Arg-CONH2) was synthesized by our laboratory. TAP,
hirudin, and mouse anti-human aPC were gifts from Dr.
H. Grossenbacher, CIBA-GEIGY, and Dr. Charles Esmon,
University of Oklahoma, respectively. All conjugated/
fluorescent antibodies (fluorescein and phycoerythrin) and
recombinant annexin V were purchased from BD Bio-
sciences, San Jose, CA; goat anti-mouse IgG magnetic
beads (MagnaBind
TM) were purchased from Pierce, Rock-
ford, IL; luciferase and luciferin from Roche Applied
Science, Indianapolis, IN; and aPC and SN-59 from
HaemTech, Essex Junction, VT. The other chemicals were
purchased from either Sigma Chemical Co, St. Louis, MO,
Electron Microscopy Science, Hatfield, PA, or EMD
Chemicals, Gibbstown, NJ.
Statistical Analyses
Descriptive statistics were used to summarize the cohort
including means with standard deviations (SD) and medians
with interquartile ranges (Q1, Q3) for all continuous parame-
ters. To explore the relationship with waist circumference,
descriptive statistics of participant characteristics and makers
of platelet function were also reported for each of three strata
defined by waist circumference <30, 30≤35, and >35 in. The
linear relationship between waist circumference and each
clinical parameter was assessed using Spearman correlation
(ρ). Similar correlation analyses were performed for each
component of metabolic syndrome with markers of platelet
function. For testing independent associations, multivariable
linear regression was performed with each platelet parameter
modeled using the primary components of metabolic
syndrome as the explanatory variables. Due to skewed
distributions for most of the platelet and microvesicle
parameters as well as for triglycerides and fasting blood
glucose, a probit transformation was applied to the ranked
values of each, thus producing normal distributional proper-
ties. To avoid the issue of co-linearity between the two blood
pressure parameters, only systolic blood pressure was
included as a covariate in multivariable regression models.
All analyses were performed using the SAS statistical
software package (version 9.1, SAS Institute Inc., Cary,
NC). With a sample size of 100 subjects, a correlation
coefficient of 0.28 would have been detectable with 80%
power at a significance level of 0.05. Although multiple
hypothesis tests were carried out, a nominal two-sided
significance level of 0.05 was used with no formal
adjustment for multiple testing. Given that about 120
pairwise correlations were tested, the expected number of
about four to six nominally significant results by chance
alone should be considered in the interpretation of these
findings.
Results
General Characteristics of Participants
The median (range) participant age and months past
menopause were 52 (range, 45–58)years and 19 (3.6–
35.8)months, respectively. Based on the inclusion criteria
for KEEPS participants, traditional cardiovascular risk
factors (Table 1) defining the 10-year cardiovascular risk
(Framingham score≤1) were low in these women. All
parameters in the complete blood count were within normal
ranges for all subjects (Table 2). As per the study entry
criteria, the CAC score for all women was <50 AU, with
the majority (n=102, 86.4%) having a score of zero.
Median (IQR) values for CIMT and RHI were 0.7 (0.6,
0.8)mm and 2.4 (1.9, 2.5), respectively.
General Platelet Functions
Spontaneous platelet microaggregation ranged from 0% to
4.5%. ATP secretion from dense granules of platelets and its
inhibition by PGE1 were similar in platelets isolated from
blood collected in citrate and hirudin plus TAP or SBTI
anticoagulant (Table 3). Basal expression of P-selectin and
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granules in response to TRAP as determined by the
expression of surface P-selectin, in contrast to the response
to ADP which showed a substantial distribution of values
(Table 3). In contrast, the percentage of platelets expressing
the fibrinogen-binding conformation of integrin αIIbβ3 as
reflected by PAC-1 binding was greater in response to ADP
than to TRAP, which activated PAC1 binding in fewer than
20% of platelets in most samples (Table 3). Plasma
concentration of aPC, a reflection of endogenous thrombin
generation or endothelial protein C receptor (EPCR) expres-
sion, ranged from 0 to10.6 ng/mL (n=116).
Correlation of Platelet Functions with Criteria for Metabolic
Syndrome
Sixty-three of 118 women had at least one of the pentad
characterizing metabolic syndrome. Twenty of 118 women
(14%) met the criteria for metabolic syndrome. Only ATP
secretion from platelets was significantly different between
women, defined as having metabolic syndrome compared
with those without (Table 4). Combinations of criterion by
which women met the definition for metabolic syndrome
were heterogeneous (Table 5). Since waist circumference
was the only consistent parameter identifying women with
metabolic syndrome, other cardiovascular risk factors were
summarized by waist circumference groupings and tested
for a correlation with continuous values for waist circum-
ference (Table 6). With the exception of age and aPC, the
other clinical cardiovascular risk factors evaluated in this
study demonstrated a significant correlation with waist
circumference (Table 6).
Platelet characteristics and functions that correlated with
components of metabolic syndrome included total number
of platelets which correlated positively with waist circum-
ference. Inhibition of ATP secretion by PGE1 correlated
positively with waist circumference in platelets collected in
hirudin and negatively with HDL-C regardless of the
anticoagulant (Table 7). ATP secretion correlated negatively
with fasting blood glucose. Basal expression of P-selectin
Characteristic Mean ± SD Median IQR: Q1, Q3
Age (years) 52.4±2.4 52.0 51.0, 58.0
Menopausal age (months) 19.3±9.1 19.0 11.7, 25.8
Follicle stimulating hormone (mIU/L) 86.2±33.7 79.0 62.6, 107.0
17β-estradiol (pg/mL) 22.0±9.1 20.0 20.0, 21.0
Thyroid stimulating hormone (mIU/mL) 2.2±1.2 2.1 10.3, 3.0
Body mass index (kg/m
2) 27.1±4.2 26.7 24.1, 30.7
Waist circumference (cm), n=114 84.4±11.9 83.3 76.0, 91.0
Fasting glucose (mg/dL), n=115 92.5±8.3 92.0 87.0, 98.0
Total cholesterol (mg/dL), n=115 217.6±30.7 218.0 200.0, 238.0
HDL-C (mg/dL), n=115 61.1±15.3 61.0 50.0, 70.0
LDL-C (mg/dL), n=115 133.1±29.6 136.0 114.0, 150.0
Triglycerides (mg/dL), n=115 95.8±46.7 85.0 66.0, 117.0
Systolic blood pressure (mmHg) 122.2±14.0 121.0 112.5, 130.0
Diastolic blood pressure (mmHg) 75.4±8.0 76.0 70.0, 82.0
hs-CRP (pg/mL), n=112 2.0±2.2 1.3 0.6, 2.4
Table 1 General characteristics
of women in whom platelet
functions were determined
n=118
HDL-C high-density lipoprotein
cholesterol, LDL-C low-density
lipoprotein cholesterol, hs-CRP
high-sensitivity C-reactive
protein
Variable (n=118) Mean±SD Median IQR: Q1, Q3
Hemoglobin (g/dL) 13.7±0.8 13.8 13.2, 14.2
Hematocrit (%) 39.8±2.2 39.7 38.4, 41.1
Platelets (in citrate, 10
3/μL)
a 235.3±49.1 232.0 201.0, 267.0
Platelets (in EDTA, 10
3/μL)
b 240.6±49.1 234.5 209.0, 269.5
WBC (10
9/L) 5.3±1.4 5.0 4.2,6.3
Neutrophils (%) 57.9±6.9 58.0 53.0, 62.0
Lymphocytes (%) 31.8±6.5 31.0 27.0, 36.0
Monocytes (%) 7.1±1.7 7.0 6.0, 8.0
Eosinophils (%) 2.4±1.6 2.0 1.0, 3.0
Basophils (%) 0.5±0.5 0.0 0.00, 1.00
Table 2 Blood cell counts in
women in whom platelets were
studied
an=114
bn=116
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stimulation correlated negatively with both systolic and
diastolic blood pressures. None of the studied platelet
functions were significantly correlated with triglycerides by
univariate assessment.
Among the subset of subjects in whom plasma micro-
vesicles were measured (n=58), neither total number of
procoagulant (phosphatidylserine-positive by annexin V
binding) microvesicles or those expressing vascular cell
adhesion molecule-1 or tissue factor correlated with any of
the components of metabolic syndrome (data not shown).
Microvesicles expressing intercellular adhesion molecule-1
(ICAM-1) correlated with triglycerides (ρ=0.32, p=0.017).
Microvesicles derived from monocytes (CD14) correlated
positively with systolic blood pressure (ρ=0.31, p=0.016);
other microvesicles [platelets (CD42a), leukocytes (CD45),
or endothelium-(CD62) derived] did not correlate signifi-
cantly with any component of metabolic syndrome from the
univariate analysis (Table 7).
Multivariable regression revealed a few strong indepen-
dent associations between components of metabolic syn-
drome and different platelet functions (Table 7). Among
Platelet function Mean±SD Median IQR: Q1, Q3
ATP secretion (amol/plt)
Citrate, n=110 25.0±7.8 24.3 20.1, 28.9
Hirudin plus TAP or soybean trypsin inhibitor, n=99 27.1±9.3 26.4 21.0, 32.8
PGE1 sensitivity (% inhibition ATP secretion)
Citrate, n=108 22.3±14.9 21.3 10.7, 32.8
Hirudin plus TAP or soybean trypsin inhibitor, n=99 22.2±15.3 20.7 10.8, 31.3
Basal% expression
P-Selectin, n=112 2.1±1.1 1.9 1.4, 2.6
PAC-1 binding, n=114 1.0±0.6 0.9 0.6, 1.2
P-Selectin (% positive)
ADP, n=112 65.1±11.9 67.3 55.9, 75.2
TRAP, n=114 91.8±3.2 92.2 90.3, 94.1
PAC-1 (% positive)
ADP, n=114 75.3±15.5 78.6 67.4, 88.4
TRAP, n=115 15.4±10.0 14.1 8.1, 20.5
Table 3 Summary of
platelet functions in recently
menopausal women
ADP adenosine diphosphate,
ATP adenosine triphosphate,
PAC1 integrin αIIBβ3 fibrinogen
binding, PGE1 prostaglandin E1,
plt platelet, TAP tick anticoagu-
lant peptide, TRAP thrombin
receptor agonist peptide
Variable No metabolic syndrome Metabolic syndrome p value
nn
ATP Secretion (amol/plt)
Citrate 86 25.1 (20.5, 31.7) 20 22.2 (19.2, 24.1) 0.01
Hirudin plus TAP or soybean
trypsin inhibitor
78 27.9 (21.0, 33.8) 17 23.8 (21.7, 26.4) 0.05
PGE1 sensitivity (% inhibition ATP secretion)
Citrate 85 18.8 (9.7, 28.6) 19 23.8 (20.3, 36.7) 0.09
Hirudin plus TAP or soybean
trypsin inhibitor
78 19.5 (10.6, 28.1) 17 24.6 (13.0, 37.0) 0.23
Basal% expression
P-Selectin 90 2.0 (1.4, 2.6) 18 1.6 (1.3, 2.8) 0.78
PAC-1 binding 91 0.9 (0.6, 1.2) 19 1.0 (0.7, 1.3) 0.35
P-Selectin (% positive)
ADP 89 68.6 (58.7, 75.5) 19 57.7 (52.3, 75.1) 0.09
TRAP 90 92.4 (90.3, 94.4) 20 91.4 (89.9, 92.9) 0.13
PAC-1 (% positive)
ADP 91 77.6 (67.4, 87.9) 19 (55.4, 88.4) 0.73
TRAP 92 14.2 (8.4, 20.8) 19 (5.3, 19.1) 0.67
Table 4 Platelet functions in
recently menopausal women
with and without metabolic
syndrome
ADP adenosine diphosphate,
ATP adenosine triphosphate,
PAC1 integrin αIIBβ3 fibrinogen
binding, PGE1 prostaglandin E1,
plt platelet, TAP tick anticoagu-
lant peptide, TRAP thrombin
receptor agonist peptide
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circumference independent of the other components of
metabolic syndrome, as did fasting blood glucose with ATP
secretion. Also detected were independent associations for
monocyte-derived microvesicles (CD14) with waist circum-
ference as well as with systolic blood pressure (Table 8).
Relationship of Platelet Functions to Measures of Vascular
Anatomy and Endothelial Function
CAC scores showed a positive correlation with triglycerides
(ρ=0.19, p=0.048). Age, systolic blood pressure, and total
cholesterol correlated with CIMT (ρ=0.20, p=0.031; ρ=
0.22, p=0.015;andρ=0.19,p=0.046,respectively).Noneof
the measured platelet functions correlated with RHI or CAC.
However, both platelet-derived microvesicles (CD42a) and
annexin V-positive microvesicles correlated with CIMT (ρ=
0.29, p=0.028 and ρ=0.33, p=0.010, respectively; n=58).
Discussion
This study provides the first comprehensive analysis of
platelet functions and cell-derived microvesicles in a group
of women in whom overall immediate cardiovascular
disease risk is low but longitudinal risk will increase due
to their menopausal status [18–20]. The present study
identifies unique platelet characteristics and their relation-
ship to modifiable cardiovascular risk factors contributing
Table 6 Cardiovascular risk factors and waist circumference (WC) in newly menopausal women
Risk factor WC <30 in. (n=27) WC 30–35 in. (n=45) WC >35 in. (n=42) Spearman correlation
a
(n=114
b)
p value
Median IQR Median IQR Median IQR ρ 95% CI
Age 52.0 (51.0, 53.0) 52.0 (51.0, 54.0) 53.0 (51.0, 54.0) 0.08 (−0.10–0.26) 0.379
Menopausal Mo 16.7 (12.5, 21.1) 19.2 (9.6, 25.4) 21.1 (13.3, 29.9) 0.22 (0.04–0.39) 0.016
SBP 119.0 (106.5, 126.0) 119.0 (110.0, 129.5) 128.0 (121.0, 135.5) 0.39 (0.22–0.54) 0.001
DBP 71.0 (65.5, 80.0) 74.0 (70.0, 80.0) 79.0 (73.5, 84.0) 0.33 (−0.16–0.48) 0.001
Fasting glucose 88.0 (86.0, 96.0) 93.0 (88.0, 96.0) 93.0 (87.0, 102.0) 0.26 (0.08–0.43) 0.005
TC 209.0 (183.0, 219.0) 218.0 (203.0, 241.0) 227.0 (210.0, 240.0) 0.18 (0.00–0.35) 0.053
LDL-C 122.0 (96.0, 143.0) 136.0 (117.0, 152.0) 144.0 (120.0, 163.0) 0.29 (0.11–0.45) 0.002
HDL-C 68.0 (62.0, 77.0) 61.0 (51.0, 70.0) 52.5 (47.0, 61.0) -0.42 (−0.56, −0.26) <0.001
Trig 68.0 (51.0, 101.0) 83.0 (67.0, 109.0) 95.0 (74.0, 158.0) 0.28 (0.10–0.44) 0.003
hs-CRP 0.5 (0.3, 1.5) 1.0 (0.6, 1.8) 2.0 (1.3, 4.1) 0.50 (0.34–0.63) <0.001
aPC 0.5 (0.2, 0.8) 0.5 (0.3, 1.4) 0.5 (0.2, 1.2) -0.01 (−0.20–0.17) 0.908
aPC activated protein C, DBP diastolic blood pressure, HDL-C high-density lipoprotein, hs-CRP high-sensitivity C-reactive protein, LDL-C low-
density lipoprotein, SBP systolic blood pressure, TC total cholesterol, Trig triglycerides
aSpearman correlation with waist circumference analyzed as a continuous variable
bAmong the 118 subjects, 4 were missing a waist circumference measurement
Table 5 Components of metabolic syndrome in women within 3 years
of menopause
Participant WC HDL-C FBG Trig SBP DBP
AY Y Y Y
BY Y Y
CY Y Y
DY Y Y Y
EY Y Y Y
FY Y Y Y Y
GY Y Y
HY Y Y
IY Y Y Y
JY Y Y Y
KY Y Y Y
LY Y Y Y Y Y
MY Y Y
NY Y Y
OY Y Y
PY Y Y
QY Y Y Y
RY Y Y Y Y
SY Y Y
TY Y Y
Total 20 15 13 11 10 5
DBP diabolic blood pressure, FBG fasting blood glucose, HDL-C
high-density lipoprotein cholesterol, SBP systolic blood pressure, Trig
triglycerides, WC waist circumference, Y yes
J. of Cardiovasc. Trans. Res. (2011) 4:811–822 817to the overall definition of metabolic syndrome. The novel
finding of this study is that specific components for metabolic
syndrome modulate the number of platelets, receptor-activated
platelet secretory functions, and cellular activation of the
vascular wall, which contribute to atherogenesis.
The most consistent criterion of metabolic syndrome
among these recently menopausal women was waist
circumference, a characteristic which showed a positive
correlation with time past menopause. Central adiposity,
defined by waist circumference, is associated with changes
in platelet functions in other studies, but the sex and
hormonal status of subjects from whom platelets were
derived were not documented [27]. Consistent with other
studies, the number of platelets increased with central
obesity in these recently menopausal women. Cytokines,
including interleukin-6 (IL-6) secreted from adipose tissue,
act synergistically with other cytokines and thrombopoietin
in megakaryocytopoiesis to increase platelet counts [12].
IL-6 was not measured in this study, but the IL-6 regulated
acute phase hepatic protein, hs-CRP [28], increased with
waist circumference. The contribution of other adipokines
to these effects is of interest but beyond the scope of the
present study as specific markers of adipose activation were
not measured.
Basal expression of P-selectin and PAC-1 binding was
<5%, suggesting that platelets were not activated by the
collection procedure. However, in some women, platelets
may have been partially activated in vivo prior to testing in
vitro. First, both univariate and multivariate analyses
identified significantly decreased P-selectin expression in
basal expression and in response to ADP activation with
increasing blood pressure. This relationship could reflect
the in vivo depletion of the α-granules. Measurement of
soluble P-selectin, also an estimate of platelet activation,
would confirm this speculation [29]. Measurement of
soluble P-selectin in stored plasma samples is planned
when KEEPS is closed in 2012.
In vivo activation of dense granules may occur with
increases in fasting glucose as activated ATP secretion was
negatively correlated with fasting glucose. Unlike other
studies of individuals with increased adiposity, all values
for fasting blood glucose were considered within the
normal range and none of the women were diagnosed with
type II diabetes, and only 13 individuals had fasting blood
glucose which met the criterion for metabolic syndrome.
Therefore, a major contribution of the present study is the
identification of changes in platelet functions with changes
in fasting blood glucose within a narrow range.
Platelet parameter WC HDL-C FBG Trig SBP DBP
Platelet no. (10
3/mL)
In citrate 0.26** −0.06 0.03 0.14 0.08 0.06
In EDTA 0.22* −0.05 0.03 0.09 0.06 0.04
ATP (amole/platelet)
In citrate -0.08 0.10 −0.30** -0.07 -0.13 -0.03
In hirudin -0.12 0.07 −0.26** 0.01 -0.16 0.03
% suppression by PGE1 of ATP secretion
In citrate 0.09 −0.20* 0.07 0.06 0.01 0.01
In hirudin 0.24* −0.23* 0.00 0.12 0.17 0.05
Basal% expression
P-selectin 0.01 −0.02 −0.04 −0.04 −0.21* −0.19*
PAC1 binding 0.07 0.05 0.00 −0.03 −0.11 −0.04
% positive P-selectin
ADP activation −0.11 0.04 −0.04 −0.09 −0.19* −0.21*
TRAP activation −0.10 0.08 −0.18* −0.10 −0.10 −0.07
% positive PAC1
ADP activation 0.00 −0.08 0.02 0.09 −0.09 0.01
TRAP activation 0.01 0.00 0.05 0.14 −0.13 −0.03
Microvesicles (n=58)
CD42A (platelet) −0.02 −0.02 −0.04 0.01 0.00 −0.02
CD14 (monocyte) −0.09 −0.10 0.07 0.11 0.31* 0.10
CD45 (leukocyte) 0.01 0.06 0.10 −0.18 0.19 0.14
CD62E (endothelium) −0.07 −0.13 0.24 0.25 0.23 0.06
ICAM-1 positive −0.02 −0.22 −0.07 0.32* 0.14 0.06
Table 7 Correlations between
platelet parameters and compo-
nents of metabolic syndrome
Values are shown as Spearman
coefficients
DBP diastolic blood pressure,
FBG fasting blood glucose,
HDL-C high-density lipoprotein
cholesterol, PAC1 integrin
αIIBβ3 fibrinogen binding, SBP
systolic blood pressure,
Trig triglycerides, WC waist
circumference
*p<0.05, **p<0.01
818 J. of Cardiovasc. Trans. Res. (2011) 4:811–822Intrinsic cAMP activation may have been suppressed in
vivo in some women as the ability for exogenous PGE1 to
suppress ATP secretion increased with decreases in HDL-C.
PGE1, like prostacyclin, activates adenylate cyclase to
increase cAMP, which in turn blocks several steps of
agonist-induced elevation of cytosolic Ca
2+ (a basic mecha-
nism of platelet activation) through specific protein kinases
[30]. The correlation of PGE1 suppression with waist
circumference in platelets collected in hirudin plus soybean
trypsin inhibitor, but not in platelets collected in sodium
citrate, might reflect the difference in the mechanisms of
anticoagulation specifically related to chelation of calcium.
Although HDL-C spanned a narrow range of values,
HDL-C and not LDL (data not shown) correlated with
cAMP activation in platelets, supporting the conclusion that
HDL-C and LDL-C affect different mechanisms of platelet
integrity and activation [9]. Whether these relationships
explain aspirin insensitivity in some women or whether
they will be sustained by hormonal therapy remains to be
determined as KEEPS proceeds.
Cell-derived microvesicles are released with cellular
activation. Therefore, changes in monocyte-, endothelium-,
and platelet-derived microvesicles with increases in blood
pressureareconsistentwithinvivoactivationofvascularcells
and cell–cell interactions, leading to increases in CIMT and
progressionofplaque[31–35]. Relationships of these specific
cell-derived microvesicles with specific canonical risk factors
for cardiovascular disease in these recently menopausal,
asymptomatic women identify potential biomarkers which
may help stratify overall cardiovascular risk for early
intervention. For example, endothelium-derived microve-
sicles increased with blood pressure, suggesting some
endothelial activation which may account for the broad
range of normal values of RHI [36, 37]. The relationship of
triglycerides with CAC is consistent with a relationship to
myocardial infarction reported by others [6], and the
expression of fibrinogen receptors in platelets and ICAM-
positive microvesicles suggests a possible mechanism which
might affect calcification processes. The correlation of
monocyte-derived microvesicles with waist circumference
was significant only when accounting for other variables in
multivariate analysis. It is unclear why this relationship is
negative. Microvesicles were measured with single anti-
bodies, and the negative correlation could reflect that
monocyte-derived microvesicles, as well as endothelium-
derived microvesicles, formed aggregates with each other or
with other cell types and were not detected. This concept
could be tested in the future by analyzing microvesicle
Platelet parameter WC HDL-C FBG Trig SBP
Platelet number
In citrate 0.010/0.028
In EDTA 0.014/0.045
ATP (amol/platelet)
In citrate <.001/0.001
In hirudin 0.027/0.067
% suppression by PGE1
In citrate 0.020/0.028
In hirudin 0.037/0.087
Basal% expression
P-selectin 0.315/0.074 0.011/0.004
PAC-1 binding
% positive P-selectin
ADP activation 0.031/0.055
TRAP activation 0.042/0.086
% positive PAC1
ADP activation 0.053/0.017
TRAP activation
Microvesicles
Platelet (CD42a)
Monocyte (CD14) 0.407/0.023 0.030/0.005
Leukocyte (CD45)
Endothelium (CD62E) 0.726/0.067 0.096/0.047
ICAM-1 positive 0.023/0.043
Annexin V positive
Table 8 Univariate/multivari-
able analysis of platelet and
microvesicle parameters
with components of metabolic
syndrome
Results displayed are p values
from univariate/multivariable
regression analyses if the latter
reflect a significant or borderline
association (i.e., p<0.10. Values
of p in bold denote significant
results (p<0.05) with those itali-
cized corresponding to negative
correlations (or otherwise posi-
tive correlations)
ADP adenosine diphosphate,
ATP adenosine triphosphate,
FBG fasting blood glucose,
HDL-C high-density lipoprotein
cholesterol, ICAM-1 intercellu-
lar adhesion molecule, PAC-1
integrin αIIBβ3 fibrinogen
binding, SBP systolic blood
pressure, TC total cholesterol,
TRAP thrombin receptor agonist
peptide, Trig triglycerides,
WC waist circumference
J. of Cardiovasc. Trans. Res. (2011) 4:811–822 819populations with multiple cell-specific antibodies or using
multiple cell-specific antibodies with analysis of platelet or
leukocyte gates on the flow cytometer.
The ability of platelets to undergo spontaneous micro-
aggregation, a phenomenon linked to thrombosis [38, 39],
averaged <10%, which is similar to what is observed in
other populations [25]. This test provides information about
the sensitivity of platelets to respond to threshold stimuli in
vivo. Although specific platelet functions were associated
with various components of metabolic syndrome, the net
effect in vivo may not have altered the overall thrombotic
potential in these women within 3 years of menopause.
Plasma activated protein C (aPC) is an anticoagulant
enzyme formed upon activation of protein C by the
thrombin–thrombomodulin complex on the EPCR surface
of endothelial cells, platelets, and monocytes. Changes in
aPC can reflect either thrombin bound to thrombomodulin
or the extent of endothelial protein C receptor activity,
correlating with intravascular thrombin generation, which is
known to maintain a substantial concentration in the basal
steady state [40, 41]. The lack of significant association of
aPC with any component of metabolic syndrome suggests a
low thrombotic potential consistent with the absence of
correlations between microaggregation and the various risk
factors. Whether these associations will change with
increased time past menopause and hormonal treatments
remains to be determined.
An important advantage of this study cohort is that
women were non-smokers and defined as low risk for
cardiovascular disease by Framingham criteria. Therefore,
the study provides insight into perhaps other phenotypic
characteristics, such as those associated with metabolic
syndrome, which could be incorporated into a screening
tool to better define cardiovascular risk in women at the
menopausal transition [42].
One potential criticism of the study is that significant
correlations with multiple comparisons occurred by chance.
Based on the null distribution of p values, of the 120
correlations tested, about four to six correlations nominally
significant at the 0.05 level would have occurred by chance.
Since there were 14 such correlations, more than double the
expected chance finding, and because there were relation-
ships consistent between single parameters tested in platelets
collected in different anticoagulants, it is unlikely that chance
alone explains these associations. Furthermore, the number
of results nominally significant at the 0.01 level was 3
compared with the expected number of 1. Thus, it is likely
that at least some of these findings were not type I errors,
particularly given the fact that the direction of the effects
corresponded with prior expectations.
In conclusion, in recently menopausal women, individual
components of metabolic syndrome affect specific platelet
functions and production of cell-derived microvesicles. Of
those components, waist circumference, fasting blood glu-
cose, blood pressure, and HDL-C had the strongest indepen-
dent effects. Thus, these uniquely sensitive yet detectable
variations in platelet activities may precede adverse changes
in vascular anatomy as some correlated with thickening in the
carotid artery, a measure of early atherosclerosis [43–45].
Since there is an established association of menopause with
development of the metabolic syndrome, its modulation
using hormonal therapy at the time of onset may provide an
ideal opportunity for intervention to limit the development
and progression of atherosclerotic lesion formation [22, 46,
47]. Indeed, KEEPS is designed to study the effects of
hormone therapy on atherosclerosis and a variety of other
outcomes when administered to women who have recently
become menopausal [21, 48].
As oral estrogen preparations may increase thrombotic risk
[49–53], it remains a challenge to identify those parameters in
an individual woman that may help define thrombotic risk.
KEEPS participants are randomized to transdermal, oral, or
no estrogen therapy, and follow-up over 4 years will enable
outcomes analysis of the effect of hormone therapy and its
optimal delivery route on cardiovascular and atherothrom-
botic risk while elucidating how these parameters relate to
quantifiable function of the endothelium by arterial tonometry
and assessment of vascular anatomy by CAC and CIMT.
Thus, we await future observations regarding the potential
impact of hormonal modulation on these platelet functions
and cell-derived microvesicles as they interplay with compo-
nents of the metabolic syndrome in order to provide
mechanistic insights into the endothelial substrate response
predisposing to atherogenesis during the transition to and
following menopause.
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